An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
Price : $35 *
At a glance
- Drugs Ixekizumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Proof of concept; Therapeutic Use
- 05 Dec 2018 Status changed from recruiting to completed.
- 03 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 31 May 2018.
- 04 May 2017 New trial record